BAX Q1 Deep Dive: Turnaround Progress Amid Margin Pressures and Product LaunchesHealthcare company Baxter International (
NYSE:BAX) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 2.9% year on year to...
Baxter’s (NYSE:BAX) Q1 CY2026: Strong Sales, Stock SoarsHealthcare company Baxter International (
NYSE:BAX) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 2.9% year on year to $2.7...
What To Expect From Baxter’s (BAX) Q1 EarningsHealthcare company Baxter International (
NYSE:BAX) will be announcing earnings results this Thursday before market hours. Here’s what to look for. Baxter bea...
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn DownA company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen Stocks Trade Up, What You Need To KnowWhat Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
Avanos Medical to be Acquired by American Industrial Partners for $1.27 Billion; Stock Surges 69%The medical technology landscape witnessed a seismic shift on Tuesday as Avanos Medical (
NYSE: AVNS) announced it has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.27 billion. The deal marks a significant turning point
The Teleflex Pivot: Inside the $1 Billion Share Buyback and Strategic BreakupDisclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories are as dramatic as the current transformation of Teleflex Incorporated (
NYSE: TFX). Once a darling of the "growth-at-any-cost" era, the Wayne, Pennsylvania-based company found itself [...]
2 Oversold Stocks Set for a Comeback and 1 We Brush OffThe past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whet...
The “New BD”: A Deep-Dive Research Report on Becton, Dickinson and Company (BDX) in 2026As of April 3, 2026, the medical technology landscape is undergoing a radical transformation, and few companies embody this evolution more than Becton, Dickinson and Company (
NYSE: BDX). Known colloquially as BD, the firm has spent the last two years shedding its skin, moving from a broad-based healthcare conglomerate to a high-growth, high-margin "pure-play" medical [...]
The Evolution of a MedTech Giant: A Deep Dive into Becton, Dickinson and Company (BDX)As of April 1, 2026, Becton, Dickinson and Company (
NYSE: BDX), commonly known as BD, finds itself at a historic crossroads. For decades, BD was viewed as a diversified healthcare conglomerate—a "steady Eddie" of the MedTech world that provided everything from basic syringes to complex diagnostic laboratory equipment. However, the recent completion of the Biosciences [...]
3 Reasons to Avoid BAX and 1 Stock to Buy InsteadWhat a brutal six months it’s been for Baxter. The stock has dropped 24.9% and now trades at $16.81, rattling many shareholders. This was partly driven by it...
1 Unprofitable Stock with Impressive Fundamentals and 2 That UnderwhelmUnprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
3 S&P 500 Stocks Walking a Fine LineThe S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Envista, Baxter, Artivion, Dentsply Sirona, and Cigna Stocks Trade Down, What You Need To KnowWhat Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Q4 Earnings Highs And Lows: Baxter (NYSE:BAX) Vs The Rest Of The Medical Devices & Supplies - Diversified StocksQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Baxter (
NYSE:BAX) and the best and worst performers in the medical devices & supplies - diversified industry.
1 of Wall Street’s Favorite Stock to Target This Week and 2 Facing ChallengesWall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
The Top 5 Analyst Questions From Baxter’s Q4 Earnings CallBaxter’s fourth quarter results were met with a significant negative market reaction, as the company’s top-line growth did not translate into improved profitability. Management attributed the quarter’s underperformance to a mix of unfavorable product and geographic sales, nonrecurring inventory adjustments, and higher-than-expected costs, particularly in manufacturing and tariffs. CEO Andrew Hider acknowledged, “The results in the quarter are disappointing and underscore the work ahead to improve performance and execute more consistently.” The Advanced Surgery business was a bright spot, but continued operational challenges and a new baseline for IV Solutions volumes weighed on overall results.
